- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Novavax (NVAX)
Company Profile
| Quarter (USD) | Sep 25 | Jun 25 | Mar 25 | Dec 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 283.36 mm | 283.36 mm | 283.36 mm | 283.36 mm | 283.36 mm | 283.36 mm |
| Cash burn (monthly) | (no burn) | 25.44 mm | 67.68 mm | (no burn) | (no burn) | 31.53 mm |
| Cash used (since last report) | n/a | 109.20 mm | 290.56 mm | n/a | n/a | 135.35 mm |
| Cash remaining | n/a | 174.15 mm | -7.21 mm | n/a | n/a | 148.00 mm |
| Runway (months of cash) | n/a | 6.8 | -0.1 | n/a | n/a | 4.7 |
| 13F holders | Current |
|---|---|
| Total holders | 240 |
| Opened positions | 43 |
| Closed positions | 47 |
| Increased positions | 78 |
| Reduced positions | 54 |
| 13F shares | Current |
|---|---|
| Total value | 801.71 bn |
| Total shares | 109.22 mm |
| Total puts | 8.74 mm |
| Total calls | 5.32 mm |
| Total put/call ratio | 1.6 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 15.73 mm | $126.44 bn |
| BLK BlackRock | 13.45 mm | $108.14 bn |
| Shah Capital Management | 11.15 mm | $89.64 bn |
| STT State Street | 7.70 mm | $61.92 bn |
| SNY Sanofi | 6.88 mm | $55.32 bn |
| SK Bioscience | 6.50 mm | $85.22 mm |
| D. E. Shaw & Co. | 5.79 mm | $46.55 bn |
| MS Morgan Stanley | 4.94 mm | $39.72 bn |
| UBS UBS | 4.85 mm | $39.01 bn |
| Geode Capital Management | 3.66 mm | $29.41 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 23 Jan 26 | John C Jacobs | Common Stock | Payment of exercise | Dispose F | No | No | 9.17 | 39,132 | 358.84 k | 180,797 |
| 23 Jan 26 | John C Jacobs | Common Stock | Option exercise | Acquire M | No | No | 0 | 83,197 | 0.00 | 219,929 |
| 23 Jan 26 | John C Jacobs | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 83,197 | 0.00 | 0 |
| 11 Dec 25 | Casey Mark J | Common Stock | Payment of exercise | Dispose F | No | No | 6.69 | 12,713 | 85.05 k | 61,159 |
| 11 Dec 25 | Casey Mark J | Common Stock | Option exercise | Acquire M | No | No | 0 | 41,899 | 0.00 | 73,972 |
| 11 Dec 25 | Casey Mark J | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 41,899 | 0.00 | 41,899 |
| 11 Nov 25 | Ruxandra Draghia-Akli | Common Stock | Payment of exercise | Dispose F | No | No | 7.4 | 6,048 | 44.76 k | 8,209 |
| 11 Nov 25 | Ruxandra Draghia-Akli | Common Stock | Option exercise | Acquire M | No | No | 0 | 14,257 | 0.00 | 14,257 |
| 11 Nov 25 | Ruxandra Draghia-Akli | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 14,257 | 0.00 | 28,513 |
| 29 Oct 25 | Rodgers Richard J | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,800 | 0.00 | 28,490 |